Am
Amyris
Emeryville CAFounded 2003500 employees
Private CapbiotechAcquiredOncology
Platform: Synth Bio Ferment
Market Cap
N/A
All Drugs
3
Clinical Trials
6
Failed / Terminated
0
FDA Approved
0
Drug Pipeline (3 programs)
| Drug Name | Code | Phase | Trials | Modality | Target | MOA | Indications |
|---|---|---|---|---|---|---|---|
| Pexalucimab | AMY-7613 | Phase 3 | 4 | EZH2 | RACKD | ||
| AMY-7629 | AMY-7629 | Phase 2/3 | 1 | KIF18A | PompeHeart Failure | ||
| AMY-7405 | AMY-7405 | Phase 1/2 | 1 | GLP-1R | MDSEoE |
Financial Documents
This company has been acquired — see parent company for financial filings.
Catalyst Events (5)